Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

The Lancet Oncology

Volumn 19, Issue 4, 2018, Pages 521-536

  Garassino, Marina Chiara ^a   Cho, Byoung Chul ^b   Kim, Joo Hang ^c   Mazières, Julien ^d   Vansteenkiste, Johan ^e   Lena, Hervé ^f   Corral Jaime, Jesus ^g   Gray, Jhanelle E ^h   Powderly, John ⁱ   Chouaid, Christos ^j   Bidoli, Paolo ^k   Wheatley Price, Paul ^l   Park, Keunchil ^m   Soo, Ross A ⁿ   Huang, Yifan ^o   Wadsworth, Catherine ^o   Dennis, Phillip A ^o   Rizvi, Naiyer A ^p   Paz Ares Rodriguez, Luis ^q   Novello, Silvia ^q   Hiret, Sandrine ^q   Schmid, Peter ^q   Laack, Eckart ^q   Califano, Raffaele ^q   Maemondo, Makoto ^q   Kim, Sang We ^q   Chaft, Jamie ^q   Vicente Baz, David ^q   Berghmans, Thierry ^q   Kim, Dong Wan ^q   Surmont, Veerle ^q   Reck, Martin ^q   Han, Ji Youn ^q   Holgado Martin, Esther ^q   Belda Iniesta, Cristobal ^q   Oe, Yuichiro ^q   Chella, Antonio ^q   Chopra, Akhil ^q   Robinet, Gilles ^q   Soto Parra, Hector ^q   Thomas, Michael ^q   Cheema, Parneet ^q   Katakami, Nobuyuki ^q   Su, Wu Chou ^q   Kim, Young Chul ^q   Wolf, Juergen ^q   Lee, Jong Seok ^q   Saka, Hideo ^q   Milella, Michele ^q   Ramos Garcia, Inmaculada ^q   Sibille, Anne ^q   Yokoi, Takashi ^q   Kang, Eun Joo ^q   Atagi, Shinji ^q   Spaeth Schwalbe, Ernst ^q   Nishio, Makoto ^q   Imamura, Fumio ^q   Gabrail, Nashat ^q   Veillon, Remi ^q   Derijcke, Sofie ^q   Maeda, Tadashi ^q   Zylla, Dylan ^q   Kubiak, Kendra ^q   Santoro, Armando ^q   Uy, Ma Noemi ^q   Lucien Geater, Sarayut ^q   Italiano, Antoine ^q   Kowalski, Dariusz ^q   Barlesi, Fabrice ^q   Chen, Yuh Min ^q   Spigel, David ^q   Chewaskulyong, Busyamas ^q   Garcia Gomez, Ramon ^q   Alvarez Alvarez, Rosa ^q   Yang, Chih Hsin ^q   Hsia, Te Chun ^q   Denis, Fabrice ^q   Sakai, Hiroshi ^q   Vincent, Mark ^q   Goto, Koichi ^q   Bosch Barrera, Joaquim ^q   Weiss, Glen ^q   Canon, Jean Luc ^q   Scholz, Christian ^q   Aglietta, Massimo ^q   Kemmotsu, Hirotsugu ^q   Azuma, Koichi ^q   Bradbury, Penelope ^q   Feld, Ronald ^q   Chachoua, Abraham ^q   Jassem, Jacek ^q   Juergens, Rosalyn ^q   Palmero Sanchez, Ramon ^q   Malcolm, Albert ^q   Vrindavanam, Nandagopal ^q   Kubota, Kaoru ^q   Waller, Cornelius ^q   Waterhouse, David ^q   Coudert, Bruno ^q   Mark, Zsuzsanna ^q   Satouchi, Miyako ^q   Chang, Gee Chen ^q   Herzmann, Christian ^q   Chaudhry, Arvind ^q   Giridharan, Selvaraj ^q   Hesketh, Paul ^q   Ikeda, Norihiko ^q   Boccia, Ralph ^q   Iannotti, Nichola ^q   Haigentz, Missak ^q   Reynolds, John ^q   Querol, John ^q   Nakagawa, Kazuhiko ^q   Sugawara, Shunichi ^q   Tan, Eng Huat ^q   Hirashima, Tomonori ^q   Gettinger, Scott ^q   Kato, Terufumi ^q   Takeda, Koji ^q   Juan Vidal, Oscar ^q   Mohn Staudner, Andrea ^q   Panwalkar, Amit ^q   Daniel, Davey ^q   Kobayashi, Kunihiko ^q   Ladrera, Guia Elena Imelda ^q   Schulte, Clemens ^q   Sebastian, Martin ^q   Cernovska, Marketa ^q   Coupkova, Helena ^q   Havel, Libor ^q   Pauk, Norbert ^q   Singh, Joginder ^q   Murakami, Shuji ^q   Csoszi, Tibor ^q   Losonczy, Gyorgy ^q   Price, Allan ^q   Anderson, Ian ^q   Iqbal, Mussawar ^q   Torri, Vamsee ^q   Juhasz, Erzsebet ^q   Khanani, Saleem ^q   Koubkova, Leona ^q   Levy, Benjamin ^q   Page, Ray ^q   Bocskei, Csaba ^q   Crinò, Lucio ^q   Einspahr, David ^q   Hagenstad, Christopher ^q   Juat, Necy ^q   Overton, Lindsay ^q   Garrison, Mitchell ^q   Szalai, Zsuzsanna ^q   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Yonsei University College of Medicine   (South Korea)

^c CHA University   (South Korea)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITÉ DE RENNES 1   (France)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Carolina BioOncology Institute   (United States)

^j CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^k SAN GERARDO HOSPITAL   (Italy)

^l OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^m Sungkyunkwan University School of Medicine   (South Korea)

ⁿ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^o ASTRAZENECA   (United Kingdom)

^p Department of Medicine   (United States)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DURVALUMAB; ERLOTINIB; GAMMA GLUTAMYLTRANSFERASE; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ALK PROTEIN, HUMAN; ANAPLASTIC LYMPHOMA KINASE; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA BUTYROLACTONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TETRENOLIN;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ADVERSE EVENT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; BRADYCARDIA; BRONCHITIS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIABETES INSIPIDUS; DIARRHEA; DIVERTICULITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPOKALEMIA; HYPOPITUITARISM; HYPOTENSION; HYPOTHYROIDISM; HYPOVOLEMIC SHOCK; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LIVER ATROPHY; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MENINGITIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; SCORING SYSTEM; SENSITIVITY ANALYSIS; SPINAL CORD COMPRESSION; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR CELL; UPREGULATION; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; INJECTION SITE REACTION; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

4-BUTYROLACTONE; AGED; ANAPLASTIC LYMPHOMA KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ASPARTATE AMINOTRANSFERASES; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; ERBB RECEPTORS; FATIGUE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INJECTION SITE REACTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PNEUMONIA; PROGRESSION-FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 85043475986     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30144-X     Document Type: Article

References (30)

1. Novello, S, Barlesi, F, Califano, R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:suppl 5 (2016), v1–v27.
2. Califano, R, Kerr, K, Morgan, RD, et al. Immune checkpoint blockade: a new era for non-small cell lung cancer. Curr Oncol Rep, 18, 2016, 59.
3. Marrone, KA, Brahmer, JR, Immune checkpoint therapy in non-small cell lung cancer. Cancer J 22 (2016), 81–91.
4. Kawaguchi, T, Ando, M, Asami, K, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 32 (2014), 1902–1908.
5. Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
6. Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
7. Genentech. Tecentriq (atezolizumab) prescribing information. http://www.gene.com/download/pdf/tecentriq_prescribing.pdf, 2017 (accessed Aug 29, 2017).
8. Merck Sharp & Dohme. Keytruda (pembrolizumab) summary of product characteristics. https://www.medicines.org.uk/emc/medicine/30602, 2017 (accessed Aug 29, 2017).
9. Bristol-Myers Squibb. Opdivo (nivolumab) prescribing information. http://packageinserts.bms.com/pi/pi_opdivo.pdf, 2017 (accessed Aug 29, 2017).
10. Abdel-Rahman, O, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol 101 (2016), 75–85.
11. Zhou, GW, Xiong, Y, Chen, S, Xia, F, Li, Q, Hu, J, Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: a meta-analysis of randomized clinical trials. Medicine (Baltimore), 95, 2016, e4611.
12. Bylicki, O, Paleiron, N, Margery, J, et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 12 (2017), 563–569.
13. Gainor, JF, Shaw, AT, Sequist, LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22 (2016), 4585–4593.
14. Oganesyan, V, Gao, C, Shirinian, L, Wu, H, Dall'Acqua, WF, Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 64 (2008), 700–704.
15. Stewart, R, Morrow, M, Hammond, SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3 (2015), 1052–1062.
16. Segal, NH, Hamid, O, Hwu, W, et al. A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data. Ann Oncol, 25(suppl 4), 2014, 1058PD.
17. Antonia, SJ, Brahmer, JR, Khleif, S, et al. Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Ann Oncol, 27(suppl 6), 2016, 1216PD.
18. Rebelatto, MC, Midha, A, Mistry, A, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol, 11, 2016, 95.
19. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
20. Brahmer, JR, Rizvi, NA, Lutzky, J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol, 32(suppl 15), 2014, 8021.
21. Zhang, YL, Yuan, JQ, Wang, KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7 (2016), 78985–78993.
22. Rizvi, NA, Mazières, J, Planchard, D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
23. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
24. Leighl, NB, Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 19:suppl 1 (2012), S52–S58.
25. Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
26. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
27. Rittmeyer, A, Barlesi, F, Waterkamp, D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
28. Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
29. Lee, CK, Man, J, Lord, S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol 12 (2017), 403–407.
30. Spigel, DR, Schrock, AB, Fabrizio, D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. Proc Am Soc Clin Oncol, 34(suppl 15), 2016, 9017.